LAVAL, Quebec, Oct. 21, 2015 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today responded to recent accusations made regarding its financial reporting and operations. read more
Gilead Provides Update on Investigational Compound, GS-5734, for the Treatment of Ebola Virus Disease
LONDON–(BUSINESS WIRE)–Oct. 21, 2015– Gilead Sciences, Inc. (NASDAQ:GILD) today confirmed that the company fulfilled a request for compassionate access to GS-5734, a novel nucleotide analogue in development for the potential treatment of Ebola Virus Disease (EVD). The request was received last week and drug was shipped later the same day. The compound is currently being provided to a female patient in the United Kingdom, as described earlier today by officials from the Royal Free Hospital in London. read more
Medtronic Commits $2 Million to Support Smithsonian’s National Museum of African American History and Culture
DUBLIN – Oct. 21, 2015 – Medtronic (NYSE: MDT) today announced that it will become a founding donor to the Smithsonian’s National Museum of African American History and Culture, committing $2 million over five years from Medtronic Philanthropy.
The new museum, the Smithsonian’s 19th, will be the only national museum devoted exclusively to the documentation of African American life, art, history and culture. Scheduled to open in 2016, the museum is under construction on the National Mall in Washington, D. C. on a five-acre tract adjacent to the Washington Monument read more
Allergan Issues Statement On Specialty Pharmacy Utilization
There has been recent and potentially distracting speculation regarding the use of specialty pharmacies for the distribution of pharmaceutical products by certain pharmaceutical companies. Regarding the commercial distribution of Allergan’s products, the Company does not rely on specialty pharmacies for the distribution of its products. The Company stated that approximately three percent of Allergan U.S. Branded sales are distributed through unaffiliated specialty pharmacies, the majority of which are unique specialty products, namely BOTOX® Therapeutic and ZENPEP®.
Company Does Not Rely On Specialty Pharmacies For The Distribution of Its Brand Products –
– 97% of Allergan U.S. Branded Sales Are Distributed Through Traditional Wholesale and Retail Channels –
– Company Has No Ownership of or Affiliation with Any Specialty Pharmacy –
– Anda is a Traditional Wholesaler, Not a Specialty Pharmacy
Minomic: Agreement to Begin First-In-Human Trial of Novel Prostate Cancer Imaging Agent
SYDNEY–(EON: Enhanced Online News)–Australian immuno-oncology company Minomic International Ltd has struck an important agreement to launch the first human study of its novel monoclonal antibody technology as an imaging agent to detect prostate, pancreatic and bladder cancers. read more
Zafgen, Inc. and Its CEO Sued for Securities Fraud
BOSTON, Oct. 21, 2015 /PRNewswire/ — Zafgen, Inc. (“Zafgen” or the “Company”) (NASDAQ: ZFGN) and its chief executive officer, Thomas E. Hughes, were named as defendants in a lawsuit filed by Block & Leviton LLP alleging that they violated the Federal Securities Laws.
The lawsuit, filed in Federal Court in the District of Massachusetts, docket number 1:15-cv-13618, alleges that Defendants made misleading misrepresentations about thrombotic adverse events in previous clinical trials of its leading drug candidate beloranib. Until October 16, 2015, Zafgen had only ever disclosed two thrombotic adverse events in one prior clinical trial. read more
Lilly and AstraZeneca Expand Immuno-Oncology Research Collaboration with New Combinations
INDIANAPOLIS, Oct. 22, 2015 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and AstraZeneca (NYSE: AZN) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of patients with solid tumors. read more
Veracyte Presents New Data on Gene Variants and Fusions In Thyroid Cancer Diagnosis
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2015 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, today announced findings from a new study of the largest panel of thyroid cancer-associated gene alterations to date. The results showed that well-established and more recently discovered molecular alterations that are associated with thyroid cancer were found in both confirmed benign and malignant nodules. This suggests that more research is needed to understand how gene variant and fusion information can best be used to guide physician decision-making in thyroid cancer diagnosis. The findings were presented today at the 15th Annual International Thyroid Congress (ITC) and 85th Annual Meeting of the American Thyroid Association (ATA), in Lake Buena Vista, Fla. read more
Leica Biosystems Introduces Multiple Aperio Digital Pathology Products and Product Enhancements
Leica Biosystems announces the new Aperio Image Analysis Workstation, providing customers with a powerful, entry-level solution to add quantitative analysis techniques to their research. This release also includes new versions of Aperio eSlide Manager, Aperio ImageScope and Aperio Scanners.
Two Teenage Cardiac Patients in Kochi Regain Their Healthy Lives after Successful Surgeries with 3D-Printed Heart Models
PETALING JAYA, Malaysia, Oct. 22, 2015 /PRNewswire/ — Materialise NV (NASDAQ: MTLS), a leading provider of Additive Manufacturing software and of sophisticated 3D Printing solutions in the medical and industrial markets, used its HeartPrint® service to enable surgeons in Kochi to operate on two cardiac cases previously dismissed by hospitals as too difficult. With accurate 3D-printed replicas of the young patients’ hearts, surgeons were able to visualise complex cardiac defects and formulate a detailed pre-operative plan to maximise the potential for success.